Trials / Completed
CompletedNCT00193492
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.
Detailed description
Upon determination of eligibility, patients will randomly be assigned to one of two treatment arms: * Rituximab * Rituximab + bevacizumab For every 2 patients randomized, 1 will receive treatment number 1 (rituximab), and 1 patient will receive treatment number 2 (rituximab + bevacizumab). This is not a blinded study, so both the patient and doctor will know which treatment has been assigned.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | |
| DRUG | Rituximab |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2005-09-19
- Last updated
- 2015-01-05
- Results posted
- 2014-12-12
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00193492. Inclusion in this directory is not an endorsement.